{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:48:47Z","timestamp":1790477327934,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00432-019-02927-x","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T06:11:31Z","timestamp":1556345491000},"page":"1527-1557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases"],"prefix":"10.1007","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-5326","authenticated-orcid":false,"given":"Suheil Albert","family":"Atallah-Yunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis John","family":"Kadado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Hernandez-Montfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"key":"2927_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.7326\/L17-0396","volume":"167","author":"D Arangalage","year":"2017","unstructured":"Arangalage D, Delyon J, Lermuzeaux M, Ekpe K, Ederhy S, Pages C, Lebbe C (2017) Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 167:683\u2013684. \n                    https:\/\/doi.org\/10.7326\/L17-0396","journal-title":"Ann Intern Med"},{"key":"2927_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jey191","author":"L Baldetti","year":"2018","unstructured":"Baldetti L, Melillo F, Beneduce A, Camici PG (2018) Combined checkpoint inhibitor-associated myocarditis and pulmonary vasculitis mimicking acute pulmonary embolism. Eur Heart J Cardiovasc Imaging. \n                    https:\/\/doi.org\/10.1093\/ehjci\/jey191","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2927_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","volume":"27","author":"J Behling","year":"2017","unstructured":"Behling J, Kaes J, Munzel T, Grabbe S, Loquai C (2017) New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 27:155\u2013158. \n                    https:\/\/doi.org\/10.1097\/cmr.0000000000000314","journal-title":"Melanoma Res"},{"key":"2927_CR4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/ejhf.806","volume":"19","author":"DD Berg","year":"2017","unstructured":"Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF Jr (2017) Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail 19:682\u2013685. \n                    https:\/\/doi.org\/10.1002\/ejhf.806","journal-title":"Eur J Heart Fail"},{"key":"2927_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.pcad.2009.11.006","volume":"52","author":"LA Blauwet","year":"2010","unstructured":"Blauwet LA, Cooper LT (2010) Myocarditis. Prog Cardiovasc Dis 52:274\u2013288. \n                    https:\/\/doi.org\/10.1016\/j.pcad.2009.11.006","journal-title":"Prog Cardiovasc Dis"},{"key":"2927_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-57613-8_10","volume":"1003","author":"W Bracamonte-Baran","year":"2017","unstructured":"Bracamonte-Baran W, Cihakova D (2017) Cardiac autoimmunity: myocarditis. Adv Exp Med Biol 1003:187\u2013221. \n                    https:\/\/doi.org\/10.1007\/978-3-319-57613-8_10","journal-title":"Adv Exp Med Biol"},{"key":"2927_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 14:247\u2013249. \n                    https:\/\/doi.org\/10.1200\/JOP.18.00005","journal-title":"J Oncol Pract"},{"key":"2927_CR8","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/eurheartj\/ehm076","volume":"28","author":"AL Caforio","year":"2007","unstructured":"Caforio AL et al (2007) A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28:1326\u20131333. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehm076","journal-title":"Eur Heart J"},{"key":"2927_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11886-017-0870-x","volume":"19","author":"ALP Caforio","year":"2017","unstructured":"Caforio ALP, Malipiero G, Marcolongo R, Iliceto S (2017) Myocarditis: a clinical overview. Curr Cardiol Rep 19:63. \n                    https:\/\/doi.org\/10.1007\/s11886-017-0870-x","journal-title":"Curr Cardiol Rep"},{"key":"2927_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","volume":"56","author":"Q Chen","year":"2018","unstructured":"Chen Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB (2018) Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol (Phila) 56:667\u2013671. \n                    https:\/\/doi.org\/10.1080\/15563650.2017.1401079","journal-title":"Clin Toxicol (Phila)"},{"key":"2927_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543776.2016.1176150","volume":"26","author":"M Collin","year":"2016","unstructured":"Collin M (2016) Immune checkpoint inhibitors: a patent review (2010-2015). Expert Opin Ther Pat 26:555\u2013564. \n                    https:\/\/doi.org\/10.1080\/13543776.2016.1176150","journal-title":"Expert Opin Ther Pat"},{"key":"2927_CR12","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.jacc.2007.09.008","volume":"50","author":"LT Cooper","year":"2007","unstructured":"Cooper LT et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50:1914\u20131931. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2007.09.008","journal-title":"J Am Coll Cardiol"},{"key":"2927_CR13","unstructured":"Copeland-Halperin R, Sahni GD (2018) Autoimmune Myocarditis With AV Block: Too Much of a Good Thing? JACC"},{"issue":"2","key":"2927_CR14","first-page":"1058","volume":"4","author":"AADLA Cristina","year":"2017","unstructured":"Cristina AADLA, Escudier-Villa JM, Ortega Marcos J, Silva-Melchor L (2017) Progressive exertional dyspnea and fatigue in an oncology-patient. Austin J Clin Cardiolog 4(2):1058","journal-title":"Austin J Clin Cardiolog"},{"key":"2927_CR15","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/rheumatology\/kem212","volume":"46","author":"JR Curtis","year":"2007","unstructured":"Curtis JR et al (2007) Heart failure among younger rheumatoid arthritis and Crohn\u2019s patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 46:1688\u20131693. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kem212","journal-title":"Rheumatology (Oxford)"},{"key":"2927_CR17","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085\u20132087. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030571","journal-title":"Circulation"},{"key":"2927_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/CIRCIMAGING.115.003584","volume":"9","author":"H Farhad","year":"2016","unstructured":"Farhad H et al (2016) Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging 9:15. \n                    https:\/\/doi.org\/10.1161\/circimaging.115.003584","journal-title":"Circ Cardiovasc Imaging"},{"key":"2927_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0735-1097(00)00690-2","volume":"36","author":"GM Felker","year":"2000","unstructured":"Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, Hare JM (2000) Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 36:227\u2013232","journal-title":"J Am Coll Cardiol"},{"key":"2927_CR20","doi-asserted-by":"publisher","first-page":"92 e91","DOI":"10.1016\/j.cjca.2017.09.025","volume":"34","author":"M Frigeri","year":"2018","unstructured":"Frigeri M et al (2018) Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol 34:92 e91\u201392 e93. \n                    https:\/\/doi.org\/10.1016\/j.cjca.2017.09.025","journal-title":"Can J Cardiol"},{"key":"2927_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1159\/000479958","volume":"10","author":"Y Fukasawa","year":"2017","unstructured":"Fukasawa Y et al (2017) Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol 10:809\u2013812. \n                    https:\/\/doi.org\/10.1159\/000479958","journal-title":"Case Rep Oncol"},{"key":"2927_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/CIRCRESAHA.115.306573","volume":"118","author":"G Fung","year":"2016","unstructured":"Fung G, Luo H, Qiu Y, Yang D, McManus B (2016) Myocarditis. Circ Res 118:496\u2013514. \n                    https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306573","journal-title":"Circ Res"},{"key":"2927_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/yty149","author":"C Gallegos","year":"2019","unstructured":"Gallegos C, Rottmann D, Nguyen VQ, Baldassarre LA (2019) Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. Eur Heart J Case Rep. \n                    https:\/\/doi.org\/10.1093\/ehjcr\/yty149","journal-title":"Eur Heart J Case Rep"},{"key":"2927_CR24","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23:879\u2013886. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2018-0130","journal-title":"Oncologist"},{"key":"2927_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","volume":"3","author":"BP Geisler","year":"2015","unstructured":"Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR (2015) Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 3:4. \n                    https:\/\/doi.org\/10.1186\/s40425-015-0048-2","journal-title":"J Immunother Cancer"},{"key":"2927_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-216228","author":"R Gibson","year":"2016","unstructured":"Gibson R, Delaune J, Szady A, Markham M (2016) Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. \n                    https:\/\/doi.org\/10.1136\/bcr-2016-216228","journal-title":"BMJ Case Rep"},{"key":"2927_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s11936-012-0204-7","volume":"14","author":"M Guglin","year":"2012","unstructured":"Guglin M, Nallamshetty L (2012) Myocarditis: diagnosis and treatment. Curr Treat Options Cardiovasc Med 14:637\u2013651. \n                    https:\/\/doi.org\/10.1007\/s11936-012-0204-7","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2927_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29\u201339. \n                    https:\/\/doi.org\/10.1016\/j.intimp.2018.06.001","journal-title":"Int Immunopharmacol"},{"key":"2927_CR29","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/S0025-6196(12)61286-5","volume":"64","author":"AJ Hauck","year":"1989","unstructured":"Hauck AJ, Kearney DL, Edwards WD (1989) Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 64:1235\u20131245","journal-title":"Mayo Clin Proc"},{"key":"2927_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50. \n                    https:\/\/doi.org\/10.1186\/s40425-016-0152-y","journal-title":"J Immunother Cancer"},{"key":"2927_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtho.2018.10.156","volume":"15","author":"R Imai","year":"2018","unstructured":"Imai R, Ono M, Nishimura N, Suzuki K, Komiyama N, Tamura T (2018) Fulminant myocarditis caused by an immune checkpoint inhibitor: a case report with pathological findings. J Thorac Oncol 15:15. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2018.10.156","journal-title":"J Thorac Oncol"},{"key":"2927_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-223252","author":"F Inayat","year":"2018","unstructured":"Inayat F, Masab M, Gupta S, Ullah W (2018) New drugs and new toxicities: pembrolizumab-induced myocarditis. BMJ Case Rep. \n                    https:\/\/doi.org\/10.1136\/bcr-2017-223252","journal-title":"BMJ Case Rep"},{"key":"2927_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","volume":"41","author":"V Jain","year":"2018","unstructured":"Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A (2018) Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother 41:332\u2013335. \n                    https:\/\/doi.org\/10.1097\/CJI.0000000000000239","journal-title":"J Immunother"},{"key":"2927_CR35","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.21037\/jtd.2016.10.60","volume":"8","author":"R Janardhanan","year":"2016","unstructured":"Janardhanan R (2016) Myocarditis with very high troponins: risk stratification by cardiac magnetic resonance. J Thorac Dis 8:E1333\u2013E1336. \n                    https:\/\/doi.org\/10.21037\/jtd.2016.10.60","journal-title":"J Thorac Dis"},{"key":"2927_CR36","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749\u20131755. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"2927_CR37","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.2169\/internalmedicine.0255-17","volume":"57","author":"Y Katsume","year":"2018","unstructured":"Katsume Y, Isawa T, Toi Y, Fukuda R, Kondo Y, Sugawara S, Ootomo T (2018) Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med 57:3157\u20133162. \n                    https:\/\/doi.org\/10.2169\/internalmedicine.0255-17","journal-title":"Intern Med"},{"key":"2927_CR38","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","volume":"59","author":"I Kindermann","year":"2012","unstructured":"Kindermann I et al (2012) Update on myocarditis. J Am Coll Cardiol 59:779\u2013792. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2011.09.074","journal-title":"J Am Coll Cardiol"},{"key":"2927_CR39","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/j.1600-6143.2006.01290.x","volume":"6","author":"JA Kobashigawa","year":"2006","unstructured":"Kobashigawa JA et al (2006) Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transpl 6:1377\u20131386. \n                    https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01290.x","journal-title":"Am J Transpl"},{"key":"2927_CR40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.healun.2010.11.003","volume":"30","author":"J Kobashigawa","year":"2011","unstructured":"Kobashigawa J et al (2011) Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transpl 30:252\u2013269. \n                    https:\/\/doi.org\/10.1016\/j.healun.2010.11.003","journal-title":"J Heart Lung Transpl"},{"key":"2927_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","volume":"3","author":"H Laubli","year":"2015","unstructured":"Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3:11. \n                    https:\/\/doi.org\/10.1186\/s40425-015-0057-1","journal-title":"J Immunother Cancer"},{"key":"2927_CR42","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/S0735-1097(97)00317-3","volume":"30","author":"B Lauer","year":"1997","unstructured":"Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP (1997) Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 30:1354\u20131359","journal-title":"J Am Coll Cardiol"},{"key":"2927_CR43","doi-asserted-by":"publisher","first-page":"A2375","DOI":"10.1016\/S0735-1097(18)32916-4","volume":"71","author":"EM Lopez","year":"2018","unstructured":"Lopez EM, Dunn S, Mazimba S (2018) Malignant arrhythmias in autoimmune myocarditis secondary to immune checkpoint blockade treatment. J Am College Cardiol 71:A2375. \n                    https:\/\/doi.org\/10.1016\/S0735-1097(18)32916-4","journal-title":"J Am College Cardiol"},{"key":"2927_CR44","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","volume":"101","author":"VA Love","year":"2007","unstructured":"Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A (2007) CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res 101:248\u2013257. \n                    https:\/\/doi.org\/10.1161\/circresaha.106.147124","journal-title":"Circ Res"},{"key":"2927_CR45","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755\u20131764. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"2927_CR46","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1161\/01.CIR.0000118493.13323.81","volume":"109","author":"H Mahrholdt","year":"2004","unstructured":"Mahrholdt H et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250\u20131258. \n                    https:\/\/doi.org\/10.1161\/01.CIR.0000118493.13323.81","journal-title":"Circulation"},{"key":"2927_CR47","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3324\/haematol.2017.185777","volume":"103","author":"N Martinez-Calle","year":"2018","unstructured":"Martinez-Calle N et al (2018) Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica 103:318\u2013321. \n                    https:\/\/doi.org\/10.3324\/haematol.2017.185777","journal-title":"Haematologica"},{"key":"2927_CR48","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/1556-4029.13633","volume":"63","author":"DR Matson","year":"2018","unstructured":"Matson DR, Accola MA, Rehrauer WM, Corliss RF (2018) Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J Forensic Sci 63:954\u2013957. \n                    https:\/\/doi.org\/10.1111\/1556-4029.13633","journal-title":"J Forensic Sci"},{"key":"2927_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/CMR.0000000000000251","volume":"26","author":"A Mehta","year":"2016","unstructured":"Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S (2016) Myocarditis as an immune-related adverse event with ipilimumab\/nivolumab combination therapy for metastatic melanoma. Melanoma Res 26:319\u2013320. \n                    https:\/\/doi.org\/10.1097\/CMR.0000000000000251","journal-title":"Melanoma Res"},{"key":"2927_CR50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s40425-018-0473-0","volume":"6","author":"C Monge","year":"2018","unstructured":"Monge C et al (2018) Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. J Immunother Cancer 6:150. \n                    https:\/\/doi.org\/10.1186\/s40425-018-0473-0","journal-title":"J Immunother Cancer"},{"key":"2927_CR51","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6","journal-title":"Lancet"},{"key":"2927_CR52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2017.11.026","volume":"91","author":"F Nasr","year":"2018","unstructured":"Nasr F, El Rassy E, Maalouf G, Azar C, Haddad F, Helou J, Robert C (2018) Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer 91:171\u2013173. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.11.026","journal-title":"Eur J Cancer"},{"key":"2927_CR53","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/0002-9149(84)90089-4","volume":"53","author":"MS Nieminen","year":"1984","unstructured":"Nieminen MS, Heikkila J, Karjalainen J (1984) Echocardiography in acute infectious myocarditis: relation to clinical and electrocardiographic findings. Am J Cardiol 53:1331\u20131337","journal-title":"Am J Cardiol"},{"key":"2927_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","volume":"5","author":"TG Norwood","year":"2017","unstructured":"Norwood TG et al (2017) Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5:91. \n                    https:\/\/doi.org\/10.1186\/s40425-017-0296-4","journal-title":"J Immunother Cancer"},{"key":"2927_CR55","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki T et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477\u20131483. \n                    https:\/\/doi.org\/10.1038\/nm955","journal-title":"Nat Med"},{"key":"2927_CR56","doi-asserted-by":"publisher","first-page":"e1361097","DOI":"10.1080\/2162402X.2017.1361097","volume":"6","author":"A Reuben","year":"2017","unstructured":"Reuben A et al (2017) Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6:e1361097. \n                    https:\/\/doi.org\/10.1080\/2162402X.2017.1361097","journal-title":"Oncoimmunology"},{"key":"2927_CR57","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1111\/j.1600-6143.2005.01074.x","volume":"5","author":"ER Rodriguez","year":"2005","unstructured":"Rodriguez ER, Skojec DV, Tan CD, Zachary AA, Kasper EK, Conte JV, Baldwin WM 3rd (2005) Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transpl 5:2778\u20132785. \n                    https:\/\/doi.org\/10.1111\/j.1600-6143.2005.01074.x","journal-title":"Am J Transpl"},{"key":"2927_CR58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ensci.2018.11.023","volume":"14","author":"E Rota","year":"2019","unstructured":"Rota E et al (2019) Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity. eNeurological Sci 14:4\u20135. \n                    https:\/\/doi.org\/10.1016\/j.ensci.2018.11.023","journal-title":"eNeurological Sci"},{"key":"2927_CR59","doi-asserted-by":"publisher","first-page":"mdx697.072","DOI":"10.1093\/annonc\/mdx697.072","volume":"28","author":"T Sakai","year":"2017","unstructured":"Sakai T, Sasada S, Jyo C, Ishioka K, Takahashi S, Nakamura M (2017) Acute myocarditis and pericarditis after nivolumab treatment in patients with non-small cell lung cancer. Ann Oncol 28:mdx697.072\u2013mdx697.072. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx697.072","journal-title":"Ann Oncol"},{"key":"2927_CR60","doi-asserted-by":"publisher","first-page":"107815521875586","DOI":"10.1177\/1078155218755868","volume":"15","author":"Y Samara","year":"2018","unstructured":"Samara Y, Yu CL, Dasanu CA (2018) Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. J Oncol Pharm Pract 15:1078155218755868. \n                    https:\/\/doi.org\/10.1177\/1078155218755868","journal-title":"J Oncol Pharm Pract"},{"key":"2927_CR61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.lungcan.2016.06.025","volume":"99","author":"H Semper","year":"2016","unstructured":"Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohe C (2016) Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer 99:117\u2013119. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2016.06.025","journal-title":"Lung Cancer"},{"key":"2927_CR62","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5152\/eurasianjmed.2018.18194","volume":"51","author":"M Simsek","year":"2019","unstructured":"Simsek M, Tekin SB, Bilici M (2019) Immunological agents used in cancer treatment. Eurasian J Med 51:90\u201394. \n                    https:\/\/doi.org\/10.5152\/eurasianjmed.2018.18194","journal-title":"Eurasian J Med"},{"key":"2927_CR63","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cardfail.2016.07.355","volume":"22","author":"T Tadokoro","year":"2016","unstructured":"Tadokoro T, Keshino E, Mohri M (2016) A case of acute myocarditis during treatment with anti-PD-1 antibody nivolumab in a melanoma patient. J Cardiac Fail 22:220. \n                    https:\/\/doi.org\/10.1016\/j.cardfail.2016.07.355","journal-title":"J Cardiac Fail"},{"key":"2927_CR64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/CJI.0000000000000190","volume":"41","author":"A Tajmir-Riahi","year":"2018","unstructured":"Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L (2018) Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy. J Immunother 41:35\u201338. \n                    https:\/\/doi.org\/10.1097\/CJI.0000000000000190","journal-title":"J Immunother"},{"key":"2927_CR65","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188:4876\u20134884. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1200389","journal-title":"J Immunol"},{"key":"2927_CR66","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bjc.2017.253","volume":"117","author":"RY Tay","year":"2017","unstructured":"Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, Haydon A (2017) Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer 117:921\u2013924. \n                    https:\/\/doi.org\/10.1038\/bjc.2017.253","journal-title":"Br J Cancer"},{"key":"2927_CR67","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1093\/eurheartj\/ehy485","volume":"39","author":"C Thibault","year":"2018","unstructured":"Thibault C, Vano Y, Soulat G, Mirabel M (2018) Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. Eur Heart J 39:3553. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy485","journal-title":"Eur Heart J"},{"key":"2927_CR69","doi-asserted-by":"publisher","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","volume":"2","author":"G Varricchi","year":"2017","unstructured":"Varricchi G et al (2017) Cardiotoxicity of immune checkpoint inhibitors ESMO Open 2:e000247. \n                    https:\/\/doi.org\/10.1136\/esmoopen-2017-000247","journal-title":"Cardiotoxicity of immune checkpoint inhibitors ESMO Open"},{"key":"2927_CR70","doi-asserted-by":"publisher","first-page":"174","DOI":"10.14694\/edbook_am.2012.32.174","volume":"15","author":"JS Weber","year":"2012","unstructured":"Weber JS (2012) Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ 15:174\u2013177. \n                    https:\/\/doi.org\/10.14694\/edbook_am.2012.32.174","journal-title":"Am Soc Clin Oncol Educ"},{"key":"2927_CR71","doi-asserted-by":"publisher","first-page":"812.e811","DOI":"10.1016\/j.cjca.2018.03.007","volume":"34","author":"S Yamaguchi","year":"2018","unstructured":"Yamaguchi S et al (2018) Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can J Cardiol 34:812.e811\u2013812.e813. \n                    https:\/\/doi.org\/10.1016\/j.cjca.2018.03.007","journal-title":"Can J Cardiol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-02927-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T23:11:49Z","timestamp":1587769909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-02927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2927"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-02927-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"7 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}